As an end-to-end supplier of psychedelic medicines, Optimi Health manufactures OPTI-MHCL, our novel MDMA formulation, entirely in-house and under the strictest possible standards of quality assurance. Our uniquely efficient, stable production process allows us to scale our output according to demand without complicating our supply chain logistics or compromising on purity.
With the impact of post-traumatic disorders being felt more keenly than ever as part of a worldwide mental health crisis, the continued success of clinical trials, and the reclassification of psychedelic treatments across new jurisdictions, calls for legal access to therapeutic MDMA have never been louder.
OPTI-MHCL is here to make a meaningful impact on the lives of patients in need.
Optimi is currently the only publicly listed psychedelics company licensed by Health Canada to possess, produce, assemble, sell, and supply its formulation in patient-ready encapsulated doses across global markets.
OPTI-MHCL drug candidates are being offered in 40mg, 60mg, and 120mg dosage formats and can be formulated to meet the industry-leading MAPS Phase 3 trial protocol.
In collaboration with ATMA Journey Centers, Optimi has initiated a Phase I combinatorial study that will document the safety of OPTI-MHCL, along with our natural psilocybin standardized extract and drug candidate in healthy therapist subjects.
Therapists who are provided with experiential training using both substances will in turn be able to provide greater value and higher standards of care to patients undergoing these treatments.
On February 3, 2023, the Australian Government’s Department of Health and Aged Care published its “Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists”, which expands the Authorized Prescriber Scheme under Australia’s Therapeutic Goods Administration to offer MDMA and psilocybin as of July 1, 2023.
Optimi Health has been engaged on an ongoing basis by Mind Medicine Australia, the leading Australian charitable organization advocating for psychedelic therapies for mental health treatments, to supply OPTI-MHCL for sufferers of post-traumatic stress disorders.
For Australian researchers or clinicians looking to access OPTI-MHCL by July 1, 2023, please contact us at email@example.com.
For details on our GMP facilities and the recent distribution agreement with Mind Medicine Australia, please visit our YouTube page.
Optimi Health Corp.
21 Water St #600, Vancouver, BC V6B 1A1
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
Products do not contain psilocybin